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death in mitochondrial complex I mutant
cells
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Steve P. Gygi2 and Pere Puigserver1,2
Abstract
Mitochondrial mutations cause bioenergetic defects associated with failures to use the electron transfer chain and
oxidize substrates. These defects are exacerbated under energetic stress conditions and ultimately cause cell
deterioration and death. However, little is known about cellular strategies that rescue mitochondrial stress failures and
maintain cell survival under these conditions. Here, we have designed and performed a high-throughput chemical
screen to identify small molecules that rescue human mitochondrial complex I mutations from energetic stress-
induced cell death. The top positive hits were a series of sulfonylureas that efﬁciently maintain prolonged cell survival
and growth under energetic stress conditions. The addition of galactose instead of glucose, to experimentally force
mitochondrial respiration, triggered an initial ER stress response that was associated with IRE1α-dependent
inﬂammatory signals including JNK and p38 MAP kinases in mutant cells. Sulfonylureas, similar to inhibition of IRE1α
and p38 MAP kinase, potently blocked this ER stress inﬂammatory and cell death pathway and maintained viability and
cell growth under severe energetic stress conditions. These studies reveal that sulfonylureas and speciﬁc inhibition of
the IRE1α inﬂammatory pathway protect against cell death and can be used to rescue bioenergetic failures in
mitochondrial complex I-mutated cells under stress conditions.
Introduction
Mitochondrial diseases encompass a large group of
heterogeneous disorders stemming from mutations in
either nuclear or mitochondrial genomes and result in an
overall impairment in the oxidative phosphorylation
(OXPHOS) system1. It is estimated that 1:5000 people are
affected by a mitochondrial disorder, and currently there
are no available cures2. Of the different complexes that
make up the mitochondrial respiratory chain, complex I
(CI) is the largest and mutations in CI are the most
common OXPHOS defects in patients3. Mutations in CI
cause lowered ATP production, increased reactive oxygen
species (ROS), imbalances in NAD+/NADH ratio and
impaired mitochondrial membrane potential1,4. Cur-
rently, many treatments are aimed at rescuing OXPHOS
by bypassing CI and utilizing CI-independent pathways by
using compounds such as CoQ1 or cell membrane-
permeable prodrugs of succinate5,6.
While OXPHOS is the major pathway for generating
ATP, many different cell types predominantly utilize
glycolysis in vitro, making it difﬁcult to study defects in
mitochondrial respiration. To circumvent this challenge,
cells can be cultured in media containing galactose
instead of glucose. This forces cells to use OXPHOS
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instead of glycolysis for ATP production7. While cells
without mitochondrial defects transition from glycolysis
to OXPHOS seamlessly, cells harboring mitochondrial
mutations either fail to proliferate or undergo cell death as
a consequence of impaired OXPHOS8. We and others
have used this galactose-sensitivity assay to design high-
throughput screens to identify small molecules or genes
that can either redirect oxidative metabolism or boost
mitochondrial function to increase cell viability9,10. While
glucose deprivation is employed as a method to force cells
to utilize OXPHOS, it has also been shown to trigger ER
stress and the unfolded protein response (UPR)11,12.
Three sensors in the ER become activated as a result,
these include protein kinase R (PKR)-like ER kinase
(PERK), activating transcription factor 6 (ATF6) and
inositol-requiring enzyme 1 (IRE1). Depending on the
duration and strength of the stimulus, these factors acti-
vate different effectors that either ameliorate stress and
lead to cell survival, or initiate cell death13. For example,
under severe or sustained ER stress, IREα1 can recruit
TRAF2 and ASK1 consequently activating JNK and p38
MAPKs ultimately leading to initiation of inﬂammation
and cell death14,15.
Here we identiﬁed a subset of sulfonylureas, K+ (ATP)
channel inhibitors, which convey signiﬁcant rescue of
cybrid cells harboring a human mitochondrial CI-
mutation using a positive high-throughput chemical
screen. Interestingly, while sulfonylureas did not alter
mitochondrial bioenergetic function, they strongly inhib-
ited IRE1α pro-apoptotic and inﬂammatory signaling
through p38 and JNK kinases. These studies (1) reveal
that sulfonylureas protect against cell death and can be
used to maintain cell survival in mitochondrial complex I-
mutated cells under conditions of energetic and (2)
highlight that cells harboring mitochondrial CI-defects
are more susceptible to ER stress-induced inﬂammation
and cell death.
Results
Sulfonylureas rescue a human mitochondrial complex I
mutation from energetic stress-induced cell death
In order to identify chemical compounds that rescue
mitochondrial CI-mutant cells from energetic stress-
induced cell death, we developed a high-throughput
chemical screen in which human cybrid cells harboring
a mutation (3796A>G) in the mitochondrial protein ND1
were seeded in galactose and cell viability was assessed 72
h later (Fig. 1a). As described previously, ND1-mutant
cybrid cells die in galactose media within 72 h while
control cells survive and proliferate9. A diverse library of
5056 compounds was screened in duplicate and a Z′ score
was calculated for each compound replicate. Based on the
Z′ score, compounds were classiﬁed as strong, medium, or
weak hits. One of the top hits from the screen was the
sulfonylurea glimepiride. Interestingly, an additional K+
(ATP) channel inhibitor, glyburide, was also identiﬁed as a
medium hit (Fig. 1b). Both compounds retested in house
to similar degrees (Fig. 1c). Furthermore, treatment with
glimepiride increased cell proliferation and prolonged
rescue from cell death in galactose over the course of
several weeks (Fig. 1d). To investigate the effect glime-
piride has on wildtype cells, we cultured control cells in
galactose with glimepiride. Short-term treatment of con-
trol cells in galactose with glimepiride had no effect on
cell proliferation at 72 h or after 1 week, although treat-
ment did lead to a slight decrease in cell growth after
2 weeks of treatment (Supplementary 1). We next tested
cell survival dependency on glimepiride by culturing
ND1-mutant cells in galactose with drug for 1-week then
either removing the drug or continuing treatment. Drug
withdrawal resulted in cell death at an additional 72 h,
suggesting that glimepiride is required to maintain cell
viability and proliferation (Fig. 1e).
Sulfonylureas belong to a subset of antidiabetic drugs
that are widely used to treat type-2 diabetes. In pancreatic
beta cells, they promote insulin secretion by binding to
the sulfonylurea receptor and inhibiting the K+ (ATP)-
dependent channel16. This leads to an increase in intra-
cellular calcium levels and sequentially insulin secretion.
Reportedly, these drugs have a high speciﬁcity for the
sulfonylurea receptor and are typically used in vitro in
the nanomolar range;17 however, based on the conﬁnes of
the chemical screen compounds were administered in the
micromolar range. Speciﬁcally, sulfonylureas were used at
25 μM, making it unlikely at this concentration that they
increase cell survival by exclusively acting on the K+
(ATP) channels. Nevertheless, in an effort to conﬁrm this,
we performed a dose-response curve to determine the
(see ﬁgure on previous page)
Fig. 1 High-throughput chemical screen reveals sulfonylureas rescue complex I mutants from energetic stress-induced cell death. a
Schematic of high-throughput chemical screen. b Scatterplot of Z′ scores of all small molecular compounds tested. Cutoffs for characterizing
compounds as strong, medium, or weak hits are indicated (red dashed line). Replicate A (y-axis) is plotted against replicate B (x-axis). Sulfonylureas
(purple) and p38 (blue) inhibitors are identiﬁed. c Cell survival of ND1 cells cultured in galactose treated with either glimepiride or glyburide for 72 h.
Red dashed line indicates initial seeding density. Results shown as mean ± SEM; *p < 0.05 (n= 3). d ND1 cell survival and growth over two-weeks with
glimepiride. Results shown as mean ± SEM (n= 3). e Cell survival of ND1 cells having been treated for 7 days with glimepiride in galactose conditions
followed by either continuous culturing in glimepiride or DMSO in galactose for an additional 72 h. Results shown as mean ± SEM; *p < 0.05 (n= 3)
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working range of glimepiride in conferring ND1-mutant
rescue. Cell survival increased with increasing con-
centrations of glimepiride, the most signiﬁcant rescue
occurring at the highest concentrations (25–50 μM). No
rescue was observed at concentrations below 10 μM
(Supplementary 2A). To further explore the involvement
of the K+ (ATP) channel in cell survival, we used
CRISPR/CAS9 genome editing to deplete the Kir6.2
channel that controls potassium efﬂux and is regulated by
the sulfonylurea receptor. When 60–70% depletion was
obtained at the protein level it did not result in an increase
in ND1 cell survival (Supplementary 2B and C). There-
fore, it is unlikely that the rescue observed is through the
K+ (ATP) channel.
Activation of p38 MAP kinase mediates energetic
stress-induced cell death in ND1 cells
Although ND1 cells die within 72 h, we sought to
determine if apoptotic signaling could be detected at an
earlier time point; therefore, we measured cleaved
caspase-3 and cleaved PARP protein levels in ND1-
mutants treated either with DMSO or glimepiride in
galactose at 48 h. ND1-mutants treated with DMSO were
committed to cell death at 48 h, while cells treated with
glimepiride were strongly protected from proapoptotic
signaling (Fig. 2a). To gain further insight into the
mechanism of rescue, we performed global proteomics
analyses on ND1-mutants cultured in galactose for 48 h
and found that FOS, along with other inﬂammatory
proteins such as GDF-15, IL1α, and IL1β, were sig-
niﬁcantly downregulated with glimepiride treatment
(Fig. 2b). MAPKs control the metabolic fate and viability
of cells by mediating apoptotic and inﬂammatory signal-
ing during extracellular stresses such as energetic stress18.
Interestingly, we identiﬁed the p38 inhibitor SB203580 as
a medium hit from the chemical screen (Fig. 1b). At 48 h,
both active p-JNK and p-p38 levels where highly induced
in ND1 cells cultured in galactose compared to cells
cultured in glucose or ND1 cells cultured in galactose
with glimepiride (Fig. 2c). We found that this increase in
MAPK activation was speciﬁc to ND1-mutant cells, as
control cells did not induce activation of either MAPK
when cultured in galactose (Supplementary 3A). To
determine if JNK or p38 activation was the underlying
cause of cell death, we treated ND1-mutant cells with JNK
or p38 inhibitors and measured cell survival. At 72 h, we
did not observe any increase in cell viability with
SP600125 but did see a signiﬁcant increase in cell survival
in cells treated with either p38 inhibitor, SB203580 or
SB202190, when compared to DMSO controls (Fig. 2d, e).
We next measured mRNA levels of several inﬂammatory
markers that have been shown to increase with p38
activation. Galactose induced several of these markers
such as IL1α, IL6, TNFα, TGFβ, GDF-15, and FOS, and
most of which, with the exception of TNFα were
decreased with SB203580 and glimepiride treatment
(Fig. 2f). As expected, these genes were not induced in
control cells when cultured in galactose, demonstrating
that the inﬂammatory pathway is only activated in mito-
chondrial CI-deﬁcient cells (Supplementary 3B). This data
suggests that p38 inhibition plays a crucial role in cell
survival under energetic stress conditions, and glimepiride
acts as a potent inhibitor of the p38-signaling apoptotic
pathway in ND1-mutant cells.
Both p38 inhibition and treatment with glimepiride led
to a signiﬁcant decrease in GDF-15. Interestingly, GDF-15
has been described as a biomarker for mitochondrial
dysfunction19. To gain further insight into how glime-
piride may alleviate mitochondrial-dependent energetic
stress, we investigated whether treatment with glimepiride
increased ETC activity and ATP synthesis. ATP/ADP
ratios showed no signiﬁcant changes in ATP levels with
drug treatment; additionally, basal oxygen consumption
levels from isolated mitochondria were not increased
(Supplementary 4A and B). We further assessed mito-
chondrial ETC activities of complexes I, II, and IV along
with citrate synthase (CS) activity and found CI, IV, and
CS levels to be unchanged while CII activity was slightly
reduced (Supplementary 4C and D). Since ROS is a
known activator of p38, we measured ROS levels and
found that while galactose conditions increases ROS
levels compared to glucose, glimepiride did not alter ROS
levels (Supplementary 4E)20,21. Mitochondrial membrane
potential (MMP) is a major determinant of cell death and
decreases in MMP are indicative of mitochondrial dys-
function. Culturing cells in galactose led to a marked
decrease in MMP at 48 h compared to glucose, while
glimepiride treatment led to an increase in MMP; how-
ever, glimepiride was unable to fully restore MMP to the
levels observed under glucose conditions (Supplemen-
tary 4F). Thus, we concluded that sulfonylureas do not
increase ND1-mutant cell survival in galactose by
increasing OXPHOS capacity or by reducing ROS, but
likely inhibit cell death and relieve mitochondrial stress
through a different cellular mechanism.
CI missense mutant cells are vulnerable to mitochondrial
energetic-dependent ER stress
In addition to identifying an increase in inﬂammatory
markers, global proteomics analysis also demonstrated
that cells treated with glimepiride had reduced levels of
HSP70 members, HERP1, ATF4, and CHAC1, all of
which are proteins that are responsive to ER stress sig-
naling (Fig. 2b). Moreover, ER stress is also known to
induce apoptosis via stress kinases such as p38 and JNK15.
To determine whether ER stress may play a role in ND1
cell death, we measured mRNA levels of several ER stress
genes in both control and ND1 cells. ND1-mutants had
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increased levels of ER stress markers, such as Bip/Grp78,
Atf4, Chop, and XBP1 compared to control cells in
galactose. Furthermore, treatment with glimepiride par-
tially attenuated Bip/GRP78, Chop, and sXBP1 mRNA
levels (Fig. 3a). To determine if ER stress signaling is a
stimulant in galactose-induced ND1 cell death, we treated
ND1 cells with the chemical chaperones 4-PBA and
TUDCA as well as glucosamine and measured cell via-
bility and MAPK activation11,22. TUDCA, 4-PBA, and
glucosamine all resulted in an increase in cell survival in
galactose and prevented eif2a, JNK, and p38 activation,
although they did not signiﬁcantly alter BIP/GRP78 or
CHOP protein levels (Fig. 3b, c). Taken together, this data
indicates that blocking ER stress is sufﬁcient to rescue
ND1 cells from galactose-induced cell death and that p38
plays a key role in this process.
Mitochondrial CI missense mutant cells are more
vulnerable to ER stress-induced cell death, which can be
rescued by glimepiride
To test whether ND1 cells are more sensitive to ER
stress-induced cell death and whether glimepiride works
by ameliorating ER stress, we treated control and
ND1 cells with tunicamycin in glucose conditions with or
without glimepiride. Tunicamycin treatment led to a
dose-dependent induction of cell death in ND1-mutant
cells, while glimepiride treatment increased cell survival at
high tunicamycin concentrations (75–150 nM) and cell
proliferation at lower concentrations (50 nM). Addition-
ally, an increase in ND1 cell tunicamycin-sensitivity was
observed when compared with control cells (Fig. 4a). We
next measured ER stress markers in ND1-mutants treated
with tunicamycin with either DMSO or glimepiride.
Similarly to the effect of glimepiride treatment in galac-
tose, several markers of ER stress including BIP, CHOP,
and sXBP1 were signiﬁcantly downregulated with glime-
piride treatment (Fig. 4b). Furthermore, western blot
analysis showed a reduction in GRP78/BIP, CHOP, and p-
p38 with glimepiride treatment. As expected, p-p38 levels
were also lower in control cells treated with tunicamycin
than ND1 cells treated with tunicamycin (Fig. 4c). These
results suggest that while galactose and tunicamycin elicit
an ER stress response in both mutant and control cybrids,
it is only an essential mediator of cell death in cells har-
boring the mitochondrial ND1 mutation.
We next tested a complex III Rieske knockout mouse
ﬁbroblast cell line and two additional human cybrid cell
lines (MELAS and LHON) harboring a mitochondrial
tRNA or mitochondrial CI ND6 mutation respectively, to
determine if glimepiride could be used to rescue other
mitochondrial mutant cells from galactose-induced cell
death. Interestingly, we found that glimepiride was only
able to rescue the other CI-deﬁcient cells, LHON cells
(Fig. 5a). Both the Rieske ﬁbroblasts and MELAS cybrid
cells underwent complete cell death within 12 h with or
without glimepiride treatment (data not shown). In an
attempt to explain these results, we measured ER stress
markers in glucose and galactose conditions for all three
cell lines. While LHON cells demonstrated a similar
phenotype to ND1 cells when placed in galactose, neither
Rieske nor MELAS cells exhibited an increase in ER stress
markers in galactose (Fig. 5b, c, d). Since glimepiride
conveys rescue in CI-deﬁcient cells by inhibiting the ER
stress response, it is not surprising that glimepiride failed
to protect Rieske and MELAS cells and suggests that the
mechanism of cell death is different in these cells. To
further demonstrate however, that glimepiride can rescue
cells from ER stress-induced cell death, we cultured all
three cell lines in glucose media containing tunicamycin
at different concentrations. Similarly to ND1 cells, gli-
mepiride attenuated cell death at higher concentrations of
tunicamycin and increased proliferation at lower con-
centrations (Fig. 5e, f, g). Taken together, these data shows
that glimepiride effectively rescues mitochondrial CI-
mutants from cell death during periods of energetic stress
and more broadly, protects cells from ER stress-induced
cell death.
Galactose induces an ER Stress response leading to the
activation of IRE1α and p38 in mitochondrial CI-mutant
cells
Initially when cells are cultured in galactose media, a
global induction of the UPR pathway is observed (Fig. 3a);
therefore, in an effort to delineate which arm of the ER
(see ﬁgure on previous page)
Fig. 2 Sulfonylureas inhibit pro-apoptotic signaling triggered by galactose media. a Immunoblot of Cleaved Caspase 3, Cleaved PARP, and
total PARP levels in ND1 cells treated with DMSO or glimepiride in galactose for 48 h. b Volcano plot of global proteomics analysis of cells treated
with DMSO or glimepiride in galactose. Values are expressed as glimepiride/DMSO. Dashed lines indicate cutoff for p < 0.05 and fold change is > ± 0.5
(n= 3). Proteins involved in inﬂammatory processes are indicated in red; proteins involved in ER stress signaling are indicated in green. c Immunoblot
of total and phosphorylated levels of MKK4, JNK, and p38 levels of ND1 cells in glucose or galactose with DMSO or glimpiride for 48 h. d Cell survival
of ND1 cells treated with DMSO or SP600125 in galactose. Red dashed line indicates initial seeding density. Results shown as mean ± SEM (n= 3); NS
not signiﬁcant. e Cell survival of ND1 cells treated with DMSO, SB203580, or SB212190 in galactose. Red dashed line indicates initial seeding density.
Results shown as mean ± SEM (n= 3); *p < 0.05. f mRNA levels of inﬂammatory markers from ND1 cells cultured in glucose or galactose with DMSO,
glimepiride or SB203580 (ND1-p38i) analyzed by qPCR. Results shown as mean ± SEM (n= 3); *p < 0.05
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stress response is responsible for cell death we performed
a withdrawal experiment. Since cells are dependent on
glimepiride for cell survival (Fig. 1e), we cultured cells in
galactose with glimepiride for 1 week and then either
removed the drug or continued treatment for another 48
h and measured mRNA levels of ER stress genes. Inter-
estingly, the only genes that were signiﬁcantly increased
by glimepiride withdrawal were GRP94, HERP1, EDEM,
and XBP1, all of which are induced by the IRE1α branch
of the ER stress pathway (Fig. 6a)23. Notably, in response
to ER stress IRE1α is a central mediator that activates the
inﬂammatory kinases JNK and p38, suggesting that the
IRE1α branch of the UPR might cause mitochondrial
energetic-dependent cell death in ND1-mutant cells. To
test the vulnerability of these cells to IRE1α activation, we
treated ND1 cells with the IRE1α speciﬁc inhibitors, 4μ8C
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and B I09, in galactose for 72 h and measured cell viability.
Strikingly, both IRE1α inhibitors completely blocked
splicing of XBP1 (a target of IRE1α) in galactose, and led
to a signiﬁcant increase in cell survival compared to cells
treated with DMSO (Fig. 6b, c). Interestingly, while IRE1α
inhibitors suppress both XBP1 splicing and stress kinases,
sulfonylureas completely block the inﬂammatory pathway
while only mildly repressing XBP1 splicing in comparison
to the IRE1α inhibitors (Fig. 6b, d). We next measured
whether IRE1 inhibition can blunt the increase in
inﬂammatory markers driven by galactose to a similar
degree as glimepiride treatment and found that treating
ND1 cells with 4μ8C led to a signiﬁcant decrease in IL6,
GDF-15, and FOS and a mild decrease in IL1α mRNA
levels, comparable to that of glimepiride (Fig. 6e). These
results indicate that during energetic stress, mitochondrial
CI-mutant cells activate the ER stress IRE1α pro-
inﬂammatory pathway causing cell death.
Discussion
It has been described that not only do the ER and
mitochondria physically interact, but that dysfunction of
one organelle can contribute to the dysfunction of the
other24,25. Here we demonstrated that in addition to
mitochondrial mutations leaving cells vulnerable to
energetic stress-induced cell death; they also render the
cell unable to cope with elevated ER stress. We show a
shift from glucose to galactose elicits an ER stress
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response in both control and mitochondrial CI-deﬁcient
cells; however, while control cells are able to resolve this
stress, CI-mutants have an increased sensitivity to ER
stress leading to activation of p38 by IRE1α and eventually
cell death. One possibility for these differences in cell fate,
is that an increase in ATP production is necessary for the
ATP-consuming process of chaperone protein folding and
while control cells are able to increase ATP levels to meet
this demand, mitochondrial mutants are not.
Previously, we have shown that one approach to res-
cuing CI-deﬁcient cells involves metabolic reprogram-
ming through BRD4 inhibition, which allows for
remodeling of the mitochondrial proteome and increases
the utilization of FADH2, allowing substrates to bypass a
mutant CI9. Here, we have identiﬁed an alternative
approach to rescuing CI-deﬁcient cells, independent of
increasing ETC activity and ATP synthesis. We found that
treating CI-mutants with glimepiride was sufﬁcient to
rescue cells cultured in either galactose or glucose media
containing tunicamycin. Glimepiride conveyed rescue by
suppressing ER stress levels and preventing prolonged
activation of IRE1α. We demonstrate that while glime-
piride has some effect on XBP1 splicing, it predominately
acts by inhibiting the kinase activity of IRE1α to activate
MAPK p38 and JNK. Of note, while glimepiride was able
to rescue cells with a CI-missense mutation, it was unable
to rescue cells containing a CIII or tRNA mutation. This
may be attributed to the severity of the mutations, as
MELAS and Rieske cells do not maintain any detectable
respiration as opposed to ND1 and ND6 mutants (data
not shown).
Of interest, a heavily debated topic for decades has been
the existence of mitochondrial K+ (ATP) channels and
whether they play a role in mitochondrial-induced
apoptosis26. Recent ﬁndings suggest that the mitochon-
drial K+ (ATP) channel may be composed of multiple
mitochondrial proteins including some components of
the permeability transition pore; however, the molecular
structure and protein interactions that compose the
channel remain unknown27. Although we have not
investigated the effect of glimepiride on the mitochondrial
K+ (ATP) channel, other studies have demonstrated that
glimepiride has no effect on mitochondrial K+ (ATP)
channels in ventricular myocytes using similar
concentrations, and that K+ (ATP) channel openers, not
inhibitors, are proposed to be antiapoptotic27,28.
While the primary role of the UPR is to decrease ER
stress and restore homeostasis, the UPR also plays an
important role in regulating inﬂammation. This has been
described in various pathological conditions such as
metabolic diseases, neurodegenerative disorders, and
atherosclerosis29. The UPR triggers its inﬂammatory
response through NF-κB, JNK, and inﬂammasome acti-
vation as well as through transcriptional control of cyto-
kine genes30–32. Here, we have demonstrated that several
cytokines are signiﬁcantly increased upon culturing CI-
deﬁcient cells in galactose conditions. Furthermore,
treating cells with either glimepiride or a p38 inhibitor
blunts this increase, demonstrating that p38 is responsible
for the inﬂammatory response. While it is unclear, how
the inﬂammatory response further aggravates and con-
tributes to the mitochondrial dysfunction and cell death,
it has been reported that certain cytokines negatively
impact OXPHOS33,34. Likewise, mitochondrial dysfunc-
tion has also been shown to increase inﬂammation,
although this has been primarily attributed to increases in
ROS35. Interestingly, GDF-15 has been described as a
biomarker for mitochondrial dysfunction. Several studies
suggest that GDF-15 induction promotes metabolic
adaptation and can be driven by p38 kinase activation of
CHOP36. Both global proteomics and qPCR analysis
suggest that GDF-15 is similarly regulated by p38 kinase,
as ND1-mutants show elevated levels of GDF-15 when
cultured in galactose, and glimepiride and p38 inhibition
suppress this elevation. These results raise the question of
whether ER stress is an extenuating factor in disease
progression in patients with mitochondrial disorders and
whether addressing any underlying ER stress could be
beneﬁcial.
Overall, we performed an unbiased high-throughput
chemical screen in which sulfonylureas were identiﬁed as
compounds that can rescue mitochondrial CI-deﬁcient
cells from energetic stress conditions. Although it is
unlikely that sulfonylureas will be used as a therapeutic
option for treating patients with mitochondrial diseases
due to their control over insulin secretion, this study
reveals that IRE1α and p38 inhibitors may serve as more
practical compounds in the future treatment of these
(see ﬁgure on previous page)
Fig. 5 Glimepiride protects mitochondrial-mutant cells from ER stress- induced cell death. a Cell survival of LHON cells treated with DMSO or
glimepiride in galactose for 72 h. Red dashed line indicates initial seeding density. Results shown as mean ± SEM (n= 3); *p < 0.05. b mRNA levels of
ER stress markers for LHON cells cultured in either glucose or galactose for 48 h. Results shown as mean ± SEM (n= 3); *p < 0.05. c mRNA levels of ER
stress markers for MELAS cells cultured in either glucose or galactose for 48 h. Results shown as mean ± SEM (n= 3). d mRNA levels of ER stress
markers for Rieske KO cells cultured in either glucose or galactose for 48 h. Results shown as mean ± SEM (n= 3); *p < 0.05. e Cell survival curve of
control and LHON cells, f MELAS, or g Rieske KO cells treated with DMSO or glimepiride for 48 h in the presence of tunicamycin at different dosages.
Results shown as mean ± SEM (n= 3); *p < 0.05
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disorders. In addition, we further highlight the impor-
tance of intracellular-crosstalk between the ER and the
mitochondria, particularly during alterations in nutrient
availability. Importantly, this study reveals that there may
be additional strategies worth exploring that may rescue
mitochondrial deﬁciencies besides strictly increasing ATP
production.
Materials and methods
Cell culture and treatments
Unless otherwise stated, human ND1-mutant
(3796A>G) cybrid, human MELAS (A3243G-Leucine
tRNA) cybrid, human LHON ND6 (G14459A) cybrids,
and control cybrid cells were routinely cultured in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) (Gibco) con-
taining 10% fetal bovine serum, 100 U/mL penicillin and
streptomycin, 1 mM sodium pyruvate, and 4mM L-glu-
tamine. Mouse Rieske knockout cells were cultured in the
same media, but also supplemented with 5 μg/mL uridine.
Depending on the experiment, media also contained
either 10mM galactose or 25mM glucose. For cell sur-
vival experiments: 100,000 cells were seeded directly in
galactose-media with or without compounds or in glucose
media containing varying dosages of tunicamycin. Cells
were trypsinized and counted 48 or 72 h later unless
otherwise stated.
Drug treatments included: 25 μM glimepiride unless
otherwise stated (Santa Cruz Biotechnology Inc.), 25 μm
glyburide (Sigma-Aldrich), 25 μM repaglinide (Sigma-
Aldrich), 25 μM SB203580 (Santa Cruz Biotechnology
Inc.), 2 μM SB202190 (Sigma-Aldrich), 20 μM SP600125
(Sigma-Aldrich), 1 mM sodium 4-phenylbutyrate, 500 μM
Tauroursodeoxycholic acid sodium salt (Fisher Scientiﬁc),
100 μM D-(+)-glucosamine (Sigma-Aldrich), 25 μM B I09
(Tocris), 20 μM 4 μ8C (7-hydroxy-4-methyl-2-oxo-2H-
chromene-8-carbaldehyde, Sigma), tunicamycin (Sigma-
Aldrich) at varying dosages. Drug treatments were typi-
cally performed for either 48 or 72 h in galactose media
unless otherwise noted.
CRISPR constructs: The lentiCRISPR v2 plasmid
(addgene #52961) was used to clone all CRISPR con-
structs. Guide sequences for Kir6.2 were as follows.
Kir6.2#1, 5′-CACCGAAGTGACTATTGGCTTTGGG-3′;
Kir6.2#2, 5′-CACCGGAGTGGATGCTGGTGACAC-3′.
High-throughput chemical screen
A total of 1500 human ND1-mutant (3796A>G) cybrid
cells were seeded per well of a 384-well plate (Corning
#3570) in either 40 μL volume of DMEM media (Gibco)
without glucose, with 10mM galactose and 2% FBS or
DMEM media (Gibco) with 1.25 mM Glucose, 10 mM
galactose, and 2% FBS using a Matrix well-mate. Both
negative and positive control wells also contained 0.3%
DMSO while experimental wells had 100 nL of compound
added via pin transfer immediately after seeding. Con-
centrations of compounds varied; however, most com-
pounds were administered to give a ﬁnal concentration of
10 or 25 μM. Cells were then incubated for 72 h at 37 °C
with 5% CO2. Following the 72-hour incubation period,
the 384-well plates were brieﬂy centrifuged for 1 min at
1000 rpm. The media was aspirated using an aspiration
wand and fresh media (DMEM only), was added to the
cells (40 μL/ well) using the Matrix well-mate. Fifteen-
microliters of Cell Titer Glow (Promega) substrate was
then added to each well using the Matrix well-mate. The
plates were gently vortexed for 10 s and then centrifuged
for 1 min at 1000 rpm. The plates were then immediately
read on the Perkin Elmer EnVision plate reader and the
luminescence was detected for each individual well. Two
replicates were prepared as described at the same time per
library plate. A Z′ score was determined for each experi-
mental well. This was done using the following formula:
Z′ = (x – μ)/σ; where x is the luminescence value of the
well to be standardized, μ is the mean of the experimental
well population of plate, and σ is the standard deviation of
the experimental well population of plate. Each replicate
was calculated separately. Potential hits were determined
to have Z′ score of 1.8 or higher for both replicates. A
score of 1.8–3 was considered a weak hit, >3–4 was
considered a medium hit, and >4 was considered a strong
hit.
Western blot analysis
Cells were harvested and lysed in radio-
immunoprecipitation assay (RIPA) buffer containing a
cocktail of protease (Roche) and phosphatase inhibitors
(Roche), separated by SDS-PAGE, and transferred to
Immobilon-P membranes (Millipore). The following
antibodies were used: tubulin (Millipore), cleaved caspase
3 (Asp 175) (Cell Signaling), cleaved PARP (Asp 214) (Cell
Signaling), total PARP (Cell Signaling), total JNK (Cell
Signaling), phospho-JNK (T183/Y185) (Cell Signaling),
total p38 (Cell Signaling), phospho-p38 (T180/Y182) (Cell
Signaling), total MKK4 (Cell Signaling), phospho-MKK4
(Ser257/Thr261) (Cell Signaling), GRP78 (BD Bios-
ciences), total eif2a (Cell Signaling), and phospho-eif2a
(Cell Signaling), XBP-1 s (Cell Signaling), CHOP (Cell
Signaling), and Kir6.2 (Santa Cruz). Quantiﬁcation of
western blot analysis was done using ImageJ.
Gene expression
Total RNA from cultured cells was puriﬁed using
TRIzol (Invitrogen) for cDNA synthesis (Applied Biosys-
tems high-capacity kit). Relative mRNA expression was
measured by quantitative PCR (qPCR) using SYBR green
dye (Applied Biosystems) and speciﬁc primers for genes of
interest. All primers and sequences are available upon
request.
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ADP/ATP ratio
ADP/ATP ratio was measured according to manu-
facture’s instructions using a bioluminescence assay kit
(BioVision ApoSensor).
ROS generation
ROS-sensitive probe CM-H2DCFDA (Molecular
Probes) was diluted in cell culture media and added to
cells after 2 days of appropriate drug treatment. Cells were
incubated at 37 °C for 30min and washed twice with PBS.
Cells were then trypsinized and pelleted, then resus-
pended in PBS. Fluorescence was examined by ﬂow
cytometry on a BD FACS CANTOII ﬂow cytometer (BD
Bioscience) using a 488-nm argon excitation laser.
Mitochondrial membrane potential
Tetramethylrhodamine, methyl ester (TMRM) dye
(Thermo Fisher Scientiﬁc) was diluted in cell culture
media and added to cells after 2 days of indicated culture
conditions. Cells were incubated at 37 °C for 30min and
washed twice with PBS. Cells were then trypsinized and
pelleted, then resuspended in PBS. Fluorescence was
examined by ﬂow cytometry on a BD FACS CANTOII
ﬂow cytometer (BD Bioscience) using a 488-nm argon
excitation laser.
Oxygen consumption measurements
ND1-mutant cells were cultured in galactose either in
DMSO or 25 μM glimepiride for 48 h. Cells were collected
and mitochondria was isolated in a sucrose/mannitol
buffer containing 0.5% (w/v) fatty acid free BSA (pH 7.2).
Mitochondria were spun down and resuspended in a
sucrose/mannitol based mitochondrial assay solution
(MAS). A total of 50 μL of 40 μg of mitochondria were
seeded per well in a seahorse plate on ice. Mitochondria
were spun down at 2000 × g for 20 min. Afterwards,
450 μL of MAS buffer containing 2mM malate, 10 mM
pyruvate, and 0.5 mM ADP was added to each well. The
seahorse plate containing mitochondria were brieﬂy place
at 37 °C and then transferred to the XF24 Analyzer.
Mitochondrial enzymatic activities
Crude mitochondrial fractions were isolated from ND1-
mutant cells 48 h after treatment with glimepiride by
differential centrifugation. Activities were determined for
complexes I, II, IV, and CS using a SpectraMax
M5 spectrophotometer by Molecular Devices. Activity
levels were normalized to citrate synthase activity. All
enzymatic activity assays were performed as described by
Spinazzi et al.37.
Statistical analysis
All statistics are described in ﬁgure legends. In general,
for two comparisons, an unpaired Student’s t-test was
used. For multiple comparisons, one-way ANOVA with
Bonferroni post-test was applied. Three replicates per
treatment were used as a sample size unless otherwise
stated in the ﬁgure legend. All western blot analyses were
repeated minimally three times. Statistical signiﬁcance is
represented with an asterisk where P < 0.05.
Proteomics protein extraction and protease digestion
Cell pellets were combined 1:1 with SDS lysis buffer
(4.0 % SDS w/v, 250 mM NaCl, PhosStop (Roche) phos-
phatase inhibitors, EDTA-free protease inhibitor cocktail
(Promega) and 50 mM HEPES, pH 8.5). Extracts were
reduced with 5 mM DTT (57 °C for 30 min) and cysteine
residues alkylated with iodoacetamide (14 mM) in
the dark (45 min). Extracts were puriﬁed by
methanol–chloroform precipitation and subsequent ice
cold acetone washes. Pellets were resuspended in 8M
urea containing 50 mM HEPES, pH 8.5, and protein
concentrations were measured by BCA assay (Thermo
Scientiﬁc) prior to protease digestion. A total of 200 µg of
protein extracts were diluted to 4M urea and digested
with LysC (Wako) in a 1/200 enzyme/protein ratio
overnight. Digests were diluted further to a 1.5 M urea
concentration and trypsin (Promega,) was added to a ﬁnal
1/250 enzyme/protein ratio for 6 h at 37 °C. Digests were
acidiﬁed with 20 µL of 20% formic acid (FA) to a pH ~2
and subjected to C18 solid-phase extraction (SPE) (50
mg, Sep-Pak, Waters).
Isobaric tag labeling
Isobaric labeling of peptides was performed using a 6-
plex tandem mass tag (TMT) reagents (Thermo Fisher
Scientiﬁc). TMT reagents (5 mg) were dissolved in 250 µL
dry acetonitrile (ACN) and 10 µL was added to 100 µg of
peptides dissolved in 100 µL of 200 mM HEPES, pH 8.5.
After 1 h (RT), the reaction was quenched by adding 8 µL
of 5% hydroxylamine. Labeled peptides were combined,
acidiﬁed with 20 µL of 20 % FA (pH ~2) and concentrated
via C18 SPE on Sep-Pak cartridges (50 mg).
Basic pH reversed-phase HPLC
TMT labeled peptides were solubilized in buffer A (5%
ACN, 10mM ammonium bicarbonate, pH 8.0) and
separated by an Agilent 300 Extend C18 column (5 μm
particles, 4.6 mm ID, and 220mm in length). Using an
Agilent 1100 binary pump coupled with a degasser and a
photodiode array (PDA) detector (Thermo Scientiﬁc), a
45 min linear gradient from 18 to 40% acetonitrile in 10
mM ammonium bicarbonate pH 8 (ﬂow rate of 0.8 mL/
min) separated the peptide mixtures into a total of 96
fractions (37 s). Ninety-six fractions were consolidated
into 12 samples in a checkerboard manner, acidiﬁed with
10 µL of 20% formic acid and vacuum dried. Each sample
was re-dissolved in 5% FA, desalted via StageTips, dried
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via vacuum centrifugation, and reconstituted for LC-MS/
MS analysis.
Oribtrap fusion parameters
All MS analysis was performed on an Oribtrap Fusion
Lumos (Thermo Fischer Scientiﬁc) coupled to a Proxeon
nLC-1200 ultra-high pressure liquid chromatography
(UPLC) pump (Thermo Fisher Scientiﬁc). Peptides were
separated onto a packed 100 µM inner diameter column
containing 0.5 cm of Magic C4 resin (5 μm, 100 Å,
Michrom Bioresources) followed by 40 cm of Sepax
Technologies GP-C18 resin (1.8 μm, 120 Å) and a gradient
consisting of 6–30% (ACN, 0.125% FA) over 125min at
~450 nL/min. The instrument was operated in data-
dependent mode with a 60 s (±7 ppm window) expiration
time, with FTMS1 spectra collected at 120,000 resolution
with an AGC target of 500,000 and a max injection
time of 100ms. The ten most intense ions were selected
for MS/MS and precursors were ﬁltered according to
charge state (required > 1 z). Monoisotopic precursor
selection was enabled. Isolation width was set at 0.7m/z.
ITMS2 spectra were collected at an AGC of 18,000,
max injection time of 120ms and CID collision energy of
35%. For the FTMS3 acquisition, the Orbitrap was oper-
ated at 30,000 resolution with an AGC target of 50,000
and a max injection time of 250ms and an HCD collision
energy of 55%. Synchronous-precursor-selection (SPS)
was enabled to include 10 MS2 fragment ions in the
FTMS3 spectrum.
Data processing and MS2 spectra assignment
A compendium of in-house software was used to con-
vert.raw ﬁles to mzXML format, as well as to correct
monoisotopic m/z measurements and erroneous charge
state assignments. Assignment of MS/MS spectra was
performed using the Sequest algorithm. A protein
sequence database containing Human Uniprot database
(downloaded 11/2015) as well as known contaminants
such as human keratins and reverse protein sequences
were appended. Sequest searches were performed using a
20 ppm precursor ion tolerance, requiring trypsin pro-
tease speciﬁcity, while allowing up to two missed clea-
vages. TMT tags on peptide N termini/lysine residues
(+229.162932 Da) and carbamidomethylation of cysteine
residues (+57.02146 Da) were set as static modiﬁcations
while methionine oxidation (+15.99492 Da) was set as
variable modiﬁcations. An MS2 spectra assignment false
discovery rate (FDR) of <1% was achieved by applying the
target-decoy database search strategy and ﬁltered using an
in-house linear discrimination analysis algorithm with the
following peptide ion and MS2 spectra metrics: XCorr,
peptide ion mass accuracy, charge state, peptide length,
and missed-cleavages. Peptides were further ﬁltered a 1%
protein-level false discovery rate for the ﬁnal dataset.
Calculation of TMT reporter ion intensities
For quantiﬁcation, a 0.03m/z (6-plex TMT) window
centered on the theoretical m/z value of each reporter ion,
with the maximum signal intensity from the theoretical
m/z value was recorded. Reporter ion intensities were
adjusted based on the overlap of isotopic envelopes of all
reporter ions as per manufacturer speciﬁcations. Total
signal to noise values for all peptides were summed for
each TMT channel (300 minimum) and all values were
normalized to account for variance in sample handling.
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